Navigation Links
MUSC Dedicates New Bioengineering and Drug Discovery Hubs
Date:10/21/2011

CHARLESTON, S.C., Oct. 21, 2011 /PRNewswire-USNewswire/ -- Federal, state and local dignitaries ushered in a new chapter in South Carolina's growing biomedical research effort with the dedication of a laboratory complex designed to speed up cures and treatments for major diseases.

The complex, housing 78 labs and other facilities, signifies a break from the traditional research approach by combining scientists from different fields and allowing them to communicate more effectively. The two buildings – one for bioengineering and one for drug discovery – are interconnected, as are the labs within them. By combining experts from different disciplines in modern facilities with easier access, MUSC hopes to take the science as quickly as possible from the lab to the patient's bedside with improved treatments, medications and medical devices. Cancer, Alzheimer's disease and heart disorders are just some of the medical problems scientists will study in the new complex.

The complex was named after U.S. Rep. James E. Clyburn (D-SC) for his long-standing efforts to correct health disparities in South Carolina and for his support of biomedical research. "My commitment to addressing inequities in our health care system has been a lifelong passion, and it is an important mission here at MUSC. This state-of-the-art research center is evidence of this university's commitment to improving and advancing the delivery of health care, and I am proud to be a part of it," Clyburn said.

Within the center, investigators from numerous MUSC departments share space with scientists, faculty and students from Clemson University and the University of South Carolina. Large auditoria and teleconferencing technologies allow face-to-face interaction with investigators around the world. The center also will promote more partnerships with private industry to help speed up technology transfer and intellectual property commercialization. It will house at least eight of the state-supported SmartState Center of Economic Excellence Endowed Chairs who were recruited to help drive the knowledge-based economy of the state.  The state also played a critical role in funding the construction of the buildings, with half of the cost paid through the Research University Infrastructure Act passed by the S. C. General Assembly in 2004.

"The discoveries coming out of these buildings will enable us to diagnose problems earlier and treat them more effectively, and also will help us to address health disparities that exist in our state. Our hope is that this research center will result in a stronger and more vibrant biomedical community in Charleston and South Carolina," said MUSC President Ray Greenberg.  "If you want to know what our strategic plan for addressing the health needs of this state looks like, just take a look at what will be happening in these two buildings."


'/>"/>
SOURCE Medical University of South Carolina
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2. American Oriental Bioengineering Reports Second Quarter 2011 Financial Results
3. American Oriental Bioengineering to Announce First Quarter 2011 Financial Results on May 9, 2011
4. American Oriental Bioengineering to Announce Fourth Quarter and Full Year 2010 Financial Results on March 14, 2011
5. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
6. American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid
7. American Oriental Bioengineering to Announce Third Quarter 2010 Financial Results on November 9, 2010
8. American Oriental Bioengineering to Report Second Quarter 2010 Financial Results on August 9, 2010
9. American Oriental Bioengineering Reports Third Quarter 2009 Financial Results
10. American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009
11. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):